SG11202012342WA - Constructs targeting prostate-specific membrane antigen (psma) and uses thereof - Google Patents
Constructs targeting prostate-specific membrane antigen (psma) and uses thereofInfo
- Publication number
- SG11202012342WA SG11202012342WA SG11202012342WA SG11202012342WA SG11202012342WA SG 11202012342W A SG11202012342W A SG 11202012342WA SG 11202012342W A SG11202012342W A SG 11202012342WA SG 11202012342W A SG11202012342W A SG 11202012342WA SG 11202012342W A SG11202012342W A SG 11202012342WA
- Authority
- SG
- Singapore
- Prior art keywords
- psma
- specific membrane
- membrane antigen
- constructs targeting
- targeting prostate
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464495—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862686605P | 2018-06-18 | 2018-06-18 | |
PCT/US2019/037534 WO2019245991A1 (en) | 2018-06-18 | 2019-06-17 | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012342WA true SG11202012342WA (en) | 2021-01-28 |
Family
ID=68983831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012342WA SG11202012342WA (en) | 2018-06-18 | 2019-06-17 | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220185910A1 (en) |
EP (1) | EP3806904A4 (en) |
JP (1) | JP2021526844A (en) |
CN (1) | CN112469440A (en) |
AU (1) | AU2019288136A1 (en) |
CA (1) | CA3103936A1 (en) |
IL (1) | IL279373A (en) |
PH (1) | PH12020552181A1 (en) |
SG (1) | SG11202012342WA (en) |
TW (1) | TW202015729A (en) |
WO (1) | WO2019245991A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201913245UA (en) | 2015-10-23 | 2020-02-27 | Eureka Therapeutics Inc | Antibody/t-cell receptor chimeric constructs and uses thereof |
KR20200012859A (en) | 2017-04-26 | 2020-02-05 | 유레카 쎄라퓨틱스, 인코포레이티드 | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
JP2021527431A (en) * | 2018-06-21 | 2021-10-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Bispecific anti-PSMA x anti-CD28 antibody and its use |
KR102607909B1 (en) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | Anti-CD28 composition |
WO2023215738A1 (en) * | 2022-05-02 | 2023-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions targeting gpc2 and gpc3 and their use for treating solid tumors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
DE69735294T2 (en) * | 1996-03-25 | 2006-09-21 | Medarex Inc. | SPECIFIC MONOCLONAL ANTIBODIES FOR THE EXTRACELLULAR DOMAIN OF PROTASTA SPECIFIC MEMBRANE ANTIGEN |
ES2606537T3 (en) * | 2001-10-23 | 2017-03-24 | Psma Development Company L.L.C. | Antibodies against PSMA |
PT2352763E (en) * | 2008-10-01 | 2016-06-02 | Amgen Res (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
EP3597215A1 (en) * | 2012-10-02 | 2020-01-22 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
WO2016054520A2 (en) * | 2014-10-03 | 2016-04-07 | The California Institute For Biomedical Research | Engineered cell surface proteins and uses thereof |
GB201514875D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
SG10201913245UA (en) * | 2015-10-23 | 2020-02-27 | Eureka Therapeutics Inc | Antibody/t-cell receptor chimeric constructs and uses thereof |
RU2018137110A (en) * | 2016-04-13 | 2020-05-13 | Оримабс Лтд. | ANTIBODIES AGAINST PSMA AND THEIR APPLICATION |
-
2019
- 2019-06-17 US US17/253,589 patent/US20220185910A1/en active Pending
- 2019-06-17 AU AU2019288136A patent/AU2019288136A1/en not_active Abandoned
- 2019-06-17 JP JP2020570458A patent/JP2021526844A/en active Pending
- 2019-06-17 WO PCT/US2019/037534 patent/WO2019245991A1/en unknown
- 2019-06-17 SG SG11202012342WA patent/SG11202012342WA/en unknown
- 2019-06-17 EP EP19822284.6A patent/EP3806904A4/en active Pending
- 2019-06-17 CN CN201980048331.3A patent/CN112469440A/en active Pending
- 2019-06-17 CA CA3103936A patent/CA3103936A1/en not_active Abandoned
- 2019-06-18 TW TW108121155A patent/TW202015729A/en unknown
-
2020
- 2020-12-10 IL IL279373A patent/IL279373A/en unknown
- 2020-12-14 PH PH12020552181A patent/PH12020552181A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202015729A (en) | 2020-05-01 |
CN112469440A (en) | 2021-03-09 |
EP3806904A4 (en) | 2022-04-27 |
IL279373A (en) | 2021-01-31 |
US20220185910A1 (en) | 2022-06-16 |
WO2019245991A1 (en) | 2019-12-26 |
PH12020552181A1 (en) | 2021-06-28 |
AU2019288136A1 (en) | 2021-01-07 |
EP3806904A1 (en) | 2021-04-21 |
JP2021526844A (en) | 2021-10-11 |
CA3103936A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279373A (en) | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof | |
EP3807321A4 (en) | Anti-mesothelin constructs and uses thereof | |
EP3615567A4 (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
ZA202001285B (en) | Antigen-binding proteins targeting shared antigens | |
IL275547A (en) | Antigen-binding proteins targeting shared antigens | |
HK1258274A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
DK3294333T3 (en) | CLAUDIN-18.2-SPECIFIC IMMUNE RECEPTORS AND T-CELL PITOPES | |
BR112018003339A2 (en) | fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin | |
EP3291836A4 (en) | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof | |
IL277542A (en) | Constructs targeting cd22 and uses thereof | |
MX2019004690A (en) | Antibody constructs. | |
IL276978A (en) | Il-6 antibodies and fusion constructs and conjugates thereof | |
IL288960A (en) | Radiolabeled compounds targeting the prostate-specific membrane antigen | |
IL269328A (en) | Linker units and molecular constructs comprising same | |
EP3166959A4 (en) | Targeting peptides that bind s. mutans, constructs comprising such peptides and uses thereof | |
DK3270965T3 (en) | CD48 ANTIBODIES AND CONJUGATES THEREOF | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
IL297073B1 (en) | Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens | |
SG11202009697RA (en) | Micro rna expression constructs and uses thereof | |
EP3592386A4 (en) | Anti-c5 antibodies and uses thereof | |
IL265236A (en) | Therapeutic multi-targeting constructs and uses thereof | |
DK3370440T3 (en) | HEARING, PROCEDURE AND HEARING SYSTEM. | |
DK3668272T3 (en) | HOLDER, HEATER AND PROCEDURE | |
IL289039A (en) | Prostate specific membrane antigen (psma) ligands and uses thereof |